MARKET

EBS

EBS

Emergent Bio
NYSE

Real-time Quotes | Nasdaq Last Sale

57.14
-0.33
-0.57%
After Hours: 57.14 0 0.00% 16:21 09/17 EDT
OPEN
57.35
PREV CLOSE
57.47
HIGH
57.65
LOW
56.50
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
127.20
52 WEEK LOW
55.07
MARKET CAP
3.07B
P/E (TTM)
10.39
1D
5D
1M
3M
1Y
5Y
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks · 1d ago
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
Zacks.com · 3d ago
/C O R R E C T I O N from Source -- Providence Therapeutics/
COMTEX_393326934/2669/2021-09-14T13:18:43
CNW Group · 4d ago
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
Benzinga · 4d ago
UPDATE 1-Emergent to make Providence Therapeutics potential COVID-19 vaccine
reuters.com · 4d ago
Emergent to make Providence Therapeutics' potential COVID-19 vaccine
reuters.com · 4d ago
BRIEF-Emergent Biosolutions Secures Agreement With Providence Therapeutics For Its MRNA COVID-19 Vaccine Candidate
reuters.com · 4d ago
Emergent BioSolutions Secures Multi-Year Development And Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021 Emergent BioSolutions Inc. (NYSE:EBS)
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EBS. Analyze the recent business situations of Emergent Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EBS stock price target is 85.71 with a high estimate of 120.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 392
Institutional Holdings: 50.23M
% Owned: 93.54%
Shares Outstanding: 53.70M
TypeInstitutionsShares
Increased
104
4.85M
New
33
1.50M
Decreased
108
3.68M
Sold Out
81
2.35M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Executive Director
Fuad El-Hibri
President/Chief Executive Officer/Director
Robert Kramer
Chief Financial Officer/Executive Vice President/Treasurer
Richard Lindahl
Chief Operating Officer/Executive Vice President
Adam Havey
Chief Human Resource Officer/Executive Vice President
Katherine Strei
Executive Vice President/General Counsel/Secretary
Atul Saran
Executive Vice President
Sean Kirk
Executive Vice President
Karen Smith
Lead Director/Independent Director
Ronald Richard
Director
Marvin White
Independent Director
Zsolt Harsanyi
Independent Director
Jerome Hauer
Independent Director
George Joulwan
Independent Director
Louis Sullivan
Independent Director
Kathryn Zoon
No Data
  • All
  • Financials
  • Insiders
More
About EBS
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.